---
title: "Imsidolimab in Generalized pustular psoriasis: Product information and disease description"
description: "Formulary evidence on Imsidolimab in Generalized pustular psoriasis: Product information and disease description. Covers Product description and Place of product in therapy. 76 evidence topics quoted from 64 sources."
canonical: "https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imsidolimab in Generalized pustular psoriasis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Product name, regulatory status, and anticipated FDA action

> “Quimilza™ (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026”

Source: [Vanda Pharmaceuticals second quarter 2026 results announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2026-financial-results-302844175.html)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; BLA submitted December 2025

> “The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA”

Source: [Vanda Pharmaceuticals Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/0001347178/000162828026067886/vnda8-k10282026exhibit991.htm)

> “In December 2025, we submitted the Biologics License Application (BLA) for imsidolimab for the treatment of GPP”

Source: [Vanda Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)

> “submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab”

Source: [Vanda Pharmaceuticals BLA submission announcement (2025)](https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html)

<a id="topic-2.1.1-3"></a>

##### Launch: Anticipated in the first half of 2027

> “We do not expect that we will be commercially launching right after the PDUFA date. There will be some lag time, but hopefully we can do that within the first half of 2027.”

Source: [Vanda Pharmaceuticals earnings call transcript (2026)](https://www.investing.com/news/transcripts/earnings-call-transcript-vanda-pharmaceuticals-q1-2026-misses-eps-forecast-stock-drops-93CH-4680843)

<a id="topic-2.1.1-4"></a>

##### FDA filing acceptance

> “has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP)”

Source: [Vanda Pharmaceuticals BLA acceptance announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/16791/pdf)

<a id="topic-2.1.1-5"></a>

##### Orphan drug designation: United States

> “In July 2020, the FDA granted orphan drug designation to imsidolimab for the treatment of GPP based upon GALLOP clinical data.”

Source: [AnaptysBio (2020)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-topline-data-gallop-phase-2-clinical)

<a id="topic-2.1.1-6"></a>

##### Orphan drug designation: Japan

> “Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab”

Source: [Vanda Pharmaceuticals Japan orphan drug designation announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis-302782517.html)

<a id="topic-2.1.1-7"></a>

##### Orphan designation: European Union

> “its investigational drug imsidolimab has received Orphan Designation from the European Commission”

Source: [Vanda Pharmaceuticals European Commission orphan designation announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-granted-orphan-designation-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-by-the-european-commission-302857847.html)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Vanda Pharmaceuticals

> “Vanda will receive an exclusive global license to develop, manufacture and commercialize imsidolimab.”

Source: [Vanda Pharmaceuticals license agreement announcement (2025)](https://vandapharmaceuticalsinc.gcs-web.com/node/16241/pdf)

<a id="topic-2.1.2.1-2"></a>

###### Product names in the development update

> “Quimilza™ (imsidolimab)”

Source: [Vanda Pharmaceuticals second quarter 2026 results announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2026-financial-results-302844175.html)

<a id="topic-2.1.2.1-3"></a>

###### Drug class and molecular description

> “Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling”

Source: [Vanda Pharmaceuticals NEJM Evidence publication announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/16946/pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational formulation concentration in the GALLOP protocol

> “100 mg/mL”

Source: [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Other classification in the Dutch horizon scan

> “Interleukin inhibitor”

Source: [National Health Care Institute horizon scan (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/imsidolimab?versie=versie-3)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Investigational indication in the Dutch horizon scan

> “Imsidolimab monotherapy for treatment of generalised pustular psoriasis in adults and elderly.”

Source: [National Health Care Institute horizon scan (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/imsidolimab?versie=versie-3)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed mechanism of action

> “Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36 receptor antagonist commonly observed in patients with GPP.”

Source: [Vanda Pharmaceuticals EMA orphan designation opinion announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/17086/pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Phase 1 pharmacodynamics: duration of suppression and ex vivo assay

> “completely suppress IL-36 cytokine function for 85 days”
> “IL-36 cytokine-mediated release of IL-8 using an ex vivo pharmacodynamic assay.”

Source: [AnaptysBio (2018)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-anb020-and-anb019-clinical-data-2018/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: phase 1 healthy-volunteer study

> “half-life of ANB019 was approximately 28 days for both subcutaneous and intravenous routes of administration, with bioavailability of approximately 90%.”

Source: [AnaptysBio (2017)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-anb019-top-line-phase-1-clinical)

> “Median terminal half life ranged between 597 and 689 hours (25 to 29 days).”
> “Bioavailability was approximately 90%”

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pregnancy and lactation: GALLOP exclusion criterion

> “Pregnant or lactating females, or females who intend to become pregnant during the study period.”

Source: [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Pediatric, renal impairment, and hepatic impairment data

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Imsidolimab

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Imsidolimab on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Investigational acute-flare doses in GEMINI-1

> “750mg IV imsidolimab, 300mg IV imsidolimab or placebo”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="topic-2.1.2.10.1-2"></a>

###### Investigational regimen in GALLOP

> “750mg IV dose of imsidolimab”
> “monthly 100mg subcutaneous dose of imsidolimab beginning at Week 4 and continued through Week 12.”

Source: [AnaptysBio British Journal of Dermatology publication announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-announces-british-journal-dermatology-publication)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Administration setting in the clinical protocol

> “ANB019 should be administered in an environment under close supervision of a physician and where full resuscitation facilities are immediately available.”

Source: [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### GALLOP: prior and concomitant treatment restrictions

> “Patients were washed out of prior therapy and no concomitant therapy was permitted during the trial.”

Source: [AnaptysBio (2020)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-topline-data-gallop-phase-2-clinical)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Imsidolimab on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Comparator indication: spesolimab

> “treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.”

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="topic-2.1.2.14-2"></a>

###### Subcutaneous spesolimab 1-ml formulation: terminated NICE technology appraisal TA1144

> “Boehringer Ingelheim has confirmed that it does not intend to make an evidence submission for the appraisal.”

Source: [NICE (2026)](https://www.ncbi.nlm.nih.gov/books/NBK623517/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition

> “Generalized Pustular Psoriasis is a systemic inflammatory disease characterized by cutaneous erythema and macroscopically visible sterile pustules.”

Source: [Choon et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38691347/)

<a id="topic-2.2.1.1-2"></a>

###### Identified flare triggers

> “stress (19.4–21.4%), infections (19.4–21.4%), and treatment withdrawal (7.1–20.0%; none due to the withdrawal of steroids)”

Source: [Choon et al. (2023)](https://karger.com/drm/article/239/3/345/835953/Clinical-Characteristics-and-Outcomes-of)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Generalized pustular psoriasis

<a id="topic-2.2.1.2.1-1"></a>

###### France incidence

> “Annually, there were 0.5–0.8 new GPP cases per 100,000 people.”

Source: [Viguier et al. (2026)](https://link.springer.com/article/10.1007/s13555-026-01691-4)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Generalized pustular psoriasis

<a id="topic-2.2.1.2.2-1"></a>

###### United States prevalence

> “60 had a diagnosis of GPP (0.015%; 95% CI, 0.01-0.02)”
> “There are 150 GPP cases per million persons amongst US adults.”
> “Our reported prevalence may be an underestimation due to limited awareness about this disease, resulting in under- or misdiagnoses.”

Source: [Kam et al. (2024)](https://doi.org/10.1016/j.jaad.2024.07.1134)

<a id="topic-2.2.1.2.2-2"></a>

###### England population-based cohort

> “the prevalence rate for GPP in our study in 2019 was 3.00 cases per 100 000 people”

Source: [Frysz et al. (2024)](https://academic.oup.com/bjd/article/191/4/529/7679321)

<a id="topic-2.2.1.2.2-3"></a>

###### France epidemiology

> “In 2017, the cumulative incidence and cumulative GPP age–sex standardized prevalence were 7.1 and 45.2 per million, respectively.”

Source: [Viguier et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.19901)

Additional sources: [Hagenström et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40689154/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### National Psoriasis Foundation consensus: acuity of flares and causes of death

> “GPP is a life-threatening disease that needs to be treated as quickly as possible.”
> “Acute flares of GPP can be life-threatening, with one-half of patients requiring hospitalization and a mortality rate of approximately 3 deaths per 100 patient years.”
> “most common causes of mortality include sepsis and multiorgan failure. Patients receiving biologics have lower in-hospital mortality than those receiving oral agents or corticosteroids alone.”

Source: [Armstrong et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37838256/)

<a id="topic-2.2.1.3-2"></a>

###### France survival

> “Twelve-month survival was 86.9% (GPP), 97.5% (plaque psoriasis), and 90.0% (the general population).”

Source: [Viguier et al. (2026)](https://link.springer.com/article/10.1007/s13555-026-01691-4)

<a id="topic-2.2.1.3-3"></a>

###### Flare recurrence

> “150 patients with a baseline flare were included in this analysis”
> “27.3% (n=41) experienced flare recurrence during the follow-up period (mean duration: 4.16 years).”

Source: [Morita et al. (2026)](https://medicaljournalssweden.se/actadv/article/view/45960)

<a id="topic-2.2.1.3-4"></a>

###### Five-year mortality

> “GPP patients had higher 5-year mortality than PV (HR, 1.83; 95% CI, 1.28–2.59)”

Source: [Lin et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1885617/full)

<a id="topic-2.2.1.3-5"></a>

###### United States mortality claims analysis

> “Patients with GPP exhibited an elevated mortality risk in comparison to the matched plaque-PsO and general population cohorts.”

Source: [Gottlieb et al. (2025)](https://journals.sagepub.com/doi/10.1177/24755303251344155)

<a id="topic-2.2.1.3-6"></a>

###### Mortality systematic review and meta-analysis

> “All-cause mortality was 1.78 times higher (95% confidence interval [CI]: 1.52–2.09; P < 0.0001) for GPP than for plaque psoriasis”

Source: [Strober et al. (2026b)](https://link.springer.com/article/10.1007/s13555-025-01584-y)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “Aberrant interleukin-36Ra structure and function lead to unregulated secretion of inflammatory cytokines and generalized pustular psoriasis.”

Source: [Marrakchi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21848462/)

Additional sources: [Sugiura et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23698098/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### ERASPEN consensus definitions

> “primary, sterile, macroscopically visible pustules on non-acral skin (excluding cases where pustulation is restricted to psoriatic plaques).”

Source: [Navarini et al. (2017)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.14386)

<a id="topic-2.2.1.5-2"></a>

###### International consensus: essential diagnostic criterion

> “Macroscopically visible sterile pustules on erythematous base and not restricted to the acral region or within psoriatic plaques.”

Source: [Choon et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38691347/)

<a id="topic-2.2.1.5-3"></a>

###### Japanese guidelines

> “Its contents include the diagnostic and severity classification criteria for GPP, its pathogenesis, and recommendations for the treatment of GPP.”

Source: [Fujita et al. (2018)](https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.14523)

<a id="topic-2.2.1.5-4"></a>

###### Global Delphi consensus: genetic testing

> “Genetic testing is helpful for GPP diagnosis, when available; screening for IL36RN mutations is recommended”

Source: [Puig et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18851)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Cutaneous symptoms: pain and rash during flare episodes

> “pain (61% of flare episodes [312 of 513])”
> “rash (46% [236 of 513])”

Source: [Zema et al. (2022)](https://jamanetwork.com/journals/jamadermatology/fullarticle/2794824)

<a id="topic-2.2.1.6-2"></a>

###### Constitutional symptoms: fever during flare episodes

> “fever (45% [229 of 513])”

Source: [Zema et al. (2022)](https://jamanetwork.com/journals/jamadermatology/fullarticle/2794824)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### France: comorbidities in GPP versus plaque psoriasis and general population cohorts

> “hypertension (37% vs 21% and 20%), obesity (21% vs 9% and 6%), depression (13% vs 4% and 4%)”

Source: [Viguier et al. (2026)](https://link.springer.com/article/10.1007/s13555-026-01691-4)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Generalized pustular psoriasis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Health-related quality-of-life systematic review

> “In total 44 records that reported on 20 studies met the eligibility criteria and were retained for data extraction.”

Source: [Choon et al. (2024a)](https://onlinelibrary.wiley.com/doi/10.1111/jdv.19530)

<a id="topic-2.2.1.8.1-2"></a>

###### France: patient-reported burden

> “High scores for fatigue, stress, skin and joint pain were reported, with 65% of patients at risk of mild to severe depression.”

Source: [Bulai Livideanu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11806833/)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient-reported burden

> “Dermatology Life Quality Index scores indicated a moderate to extremely large impact on QoL in nine patients (50%).”

Source: [Kole et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01483-2)

<a id="topic-2.2.1.8.1-4"></a>

###### Sweden health-related quality of life

> “The HRQoL was significantly worse in individuals with GPP compared to individuals with plaque psoriasis.”

Source: [Norlin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095275/)

<a id="topic-2.2.1.8.1-5"></a>

###### Malaysia health-related quality of life

> “DLQI and EQ-5D for the patients with GPP were 8.44 (SD: 7.12) and 0.74 (SD: 0.27), respectively.”

Source: [Seah et al. (2025a)](https://link.springer.com/article/10.1186/s13023-025-03820-2)

<a id="topic-2.2.1.8.1-6"></a>

###### Real-world evidence review

> “The impact of GPP on patients’ daily activities was significant, even in the absence of a flare.”

Source: [Bhutani and Farberg (2024)](https://link.springer.com/article/10.1007/s13555-024-01103-5)

Additional sources: [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36922363/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### United States case series

> “In the initial encounter, 35 patients (36.8%) were hospitalized and 64 (67.4%) were treated with systemic therapies.”

Source: [Noe et al. (2022)](https://www.med.upenn.edu/gelfand/assets/user-content/evaluation-of-a-case-series-of-patients-with-generalized-pustular-psoriasis-in-the-united-states.pdf)

<a id="topic-2.2.1.8.2-2"></a>

###### Economic burden systematic review

> “ten eligible studies”
> “across five countries”
> “the leading cost drivers for GPP were the costs of inpatient admissions and medications.”

Source: [Seah et al. (2025b)](https://link.springer.com/article/10.1186/s13561-025-00670-3)

<a id="topic-2.2.1.8.2-3"></a>

###### United States economic burden

> “GPP patients experienced significantly higher total healthcare costs compared to matched cohorts (GPP vs plaque psoriasis: cost ratio 1.36, 95% confidence interval (1.22, 1.50); GPP vs control: 5.58 (3.73, 8.36)).”
> “Rates of inpatient visits were 4 times higher in GPP patients and 2 times higher in PPP patients compared to their matched cohorts.”
> “GPP and PPP patients have significant economic burden due to higher direct medical and pharmacy costs.”

Source: [Hanna et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33622113/)

<a id="topic-2.2.1.8.2-4"></a>

###### United States healthcare utilization, flares, and severity

> “GPP patients who flared and had more severe disease had greater HCRU and charges.”

Source: [Noe et al. (2025)](https://journals.sagepub.com/doi/10.1177/24755303251317193)

<a id="topic-2.2.1.8.2-5"></a>

###### Finland economic burden

> “Flares were also associated with 2.5-fold higher indirect costs (cost ratio 2.5; 95% CI, 1.6–4.0; p < 0.001) compared with no flares.”

Source: [Teitsma et al. (2026)](https://medicaljournalssweden.se/actadv/article/view/44671)

<a id="topic-2.2.1.8.2-6"></a>

###### Taiwan national claims study

> “Median monthly healthcare costs were approximately twice as high among patients with GPP as among matched patients with PV.”

Source: [Chien et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13319885/)

Additional sources: [Lebwohl et al. (2025)](https://www.sciencedirect.com/science/article/pii/S0190962225025381); [Miyachi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34116101/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Generalized pustular psoriasis on Families

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 IL-36 Receptor Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### Asia-Pacific consensus

> “Spesolimab is the preferred biologic treatment for the management of acute flares”

Source: [Choon et al. (2024c)](https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.17471)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 TNF Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Expert recommendations: position of cytokine-targeted biologics other than IL-36 inhibitors

> “Systemic Biologics That Target the Predominant Cytokines in Plaque Psoriasis Should Be Considered Second-Line Therapy for the Treatment of GPP”

Source: [Lynde et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01535-7)

<a id="topic-2.2.2.1.2-2"></a>

###### TNF inhibitors described in the treatment recommendations

> “adalimumab, infliximab, and certolizumab pegol”

Source: [Lynde et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01535-7)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 IL-17 Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### Asia-Pacific consensus: maintenance treatment

> “IL-17 inhibitors can be used for maintenance phase”

Source: [Choon et al. (2024c)](https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.17471)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 IL-23 Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Asia-Pacific consensus: maintenance treatment

> “IL-23 inhibitors can be used for maintenance phase”

Source: [Choon et al. (2024c)](https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.17471)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Conventional Systemic Therapies

<a id="topic-2.2.2.1.5-1"></a>

###### Non-biologic systemic agents described in the treatment recommendations

> “corticosteroids (prednisone/prednisolone), cyclosporine, methotrexate, or acitretin”

Source: [Lynde et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01535-7)

<a id="topic-2.2.2.1.5-2"></a>

###### Asia-Pacific consensus: systemic corticosteroids for maintenance

> “systemic corticosteroids are not recommended as maintenance therapy”

Source: [Choon et al. (2024c)](https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.17471)

Additional sources: [Tada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11483928/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Topical Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Topical corticosteroids as maintenance or adjunctive therapy

> “topical corticosteroids may be considered in some cases for maintenance or adjunctive therapy”

Source: [Lynde et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01535-7)

<a id="topic-2.2.2.1.6-2"></a>

###### United States treatment patterns

> “Topical corticosteroids were the most frequently prescribed treatment postdiagnosis, followed by systemic corticosteroids”

Source: [Strober et al. (2026a)](https://www.sciencedirect.com/science/article/pii/S0190962225027252)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Phototherapy

<a id="topic-2.2.2.1.7-1"></a>

###### Japanese guidelines: acute-phase restriction

> “Phototherapy is not indicated for acute phase pustular psoriasis”

Source: [Fujita et al. (2018)](https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.14523)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Granulocyte and Monocyte Adsorption Apheresis

<a id="topic-2.2.2.1.8-1"></a>

###### Japanese guidelines: treatment option

> “Granulocyte/monocyte adsorption apheresis (GMA) is included as a treatment choice”

Source: [Fujita et al. (2018)](https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.14523)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Supportive Care

<a id="topic-2.2.2.1.9-1"></a>

###### Supportive care and hospital admission

> “An important aspect of current management strategies is supportive care, often including hospital admission.”

Source: [Puig et al. (2024)](https://link.springer.com/article/10.1007/s13555-024-01230-z)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

###### Summary

A treatment review included 118 publications, of which 19% reported clinical trial results. A separate biologics meta-analysis identified moderate heterogeneity and publication bias as limitations affecting reliability. In a U.S. flare-episode analysis, 122 of 513 episodes (24%) had no dermatologic treatment in the interval encompassing the 30 days before, during, and 30 days after the flare. These findings describe limitations of the evidence base and observed treatment delivery; they do not establish comparative efficacy between imsidolimab and existing therapies.

Source: [Puig et al. (2024)](https://link.springer.com/article/10.1007/s13555-024-01230-z); [Chen et al. (2024)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1462158/full); [Zema et al. (2022)](https://jamanetwork.com/journals/jamadermatology/fullarticle/2794824)

<a id="topic-2.2.2.1.10-2"></a>

###### Treatment gaps during flare episodes

> “(24% [122 of 513]) had no dermatologic treatment 30 days before, during, or 30 days after a flare episode.”

Source: [Zema et al. (2022)](https://jamanetwork.com/journals/jamadermatology/fullarticle/2794824)

<a id="topic-2.2.2.1.10-3"></a>

###### Biologics systematic review and single-arm meta-analysis

> “Moderate heterogeneity and publication bias in the included studies may affect the reliability of the results.”

Source: [Chen et al. (2024)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1462158/full)

<a id="topic-2.2.2.1.10-4"></a>

###### Treatment systematic literature review

> “In total, 118 publications were included, with only 19% of publications reporting on the results of clinical trials.”

Source: [Puig et al. (2024)](https://link.springer.com/article/10.1007/s13555-024-01230-z)

<a id="topic-2.2.2.1.10-5"></a>

###### National Psoriasis Foundation consensus: access to approved therapy

> “We strongly advocate for timely access to US Food and Drug Administration-approved therapies for GPP because delays can increase the risk of mortality in patients with this rapidly progressing disease.”
> “Spesolimab is the first US Food and Drug Administration-approved treatment that is highly effective in the treatment of GPP flares in adults.”
> “Timely access to approved therapies is critical to reducing morbidity and mortality in patients presenting with GPP.”

Source: [Armstrong et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37838256/)

<a id="topic-2.2.2.1.10-6"></a>

###### National Psoriasis Foundation consensus: diagnostic criteria should not gate treatment

> “Skin biopsy is not required for the diagnosis of GPP because histologic features may be nonspecific and it may delay treatment of this life-threatening condition.”
> “Although GPP phenotype classification criteria from the European Rare and Severe Psoriasis Expert Network and Japanese Dermatological Association are informative for clinical trials, these criteria should not be used to deny or delay treatment in clinical practice.”
> “in patients presenting with acute GPP, one should not wait to fulfill certain arbitrary definitions of GPP before initiating treatment.”

Source: [Armstrong et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37838256/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The imsidolimab phase 3 program evaluated IV treatment of GPP flares and subcutaneous maintenance among initial responders. These studies used placebo comparisons rather than an active comparison with spesolimab. The Asia-Pacific consensus included in this report identifies spesolimab as the preferred biologic for acute flares. An imsidolimab treatment position therefore remains investigational while the BLA is under review. The GALLOP protocol specifies physician supervision and availability of full resuscitation facilities for administration.

Source: [Smieszek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42047557/); [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf); [Choon et al. (2024c)](https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.17471); [Vanda Pharmaceuticals second quarter 2026 results announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2026-financial-results-302844175.html); [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)

Additional sources: [Gleeson and Mahil (2023)](https://pubmed.ncbi.nlm.nih.gov/37079741/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

No evidence found.

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Multidisciplinary management and monitoring during flares

> “A multidisciplinary approach is required for GPP disease management.”
> “Patients should be carefully monitored by a dermatologist throughout a flare”

Source: [Puig et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18851)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Global Delphi consensus: treatment goals

> “Short-term treatment goals should include pustule clearance within 7 days and prevention of pustule recurrence”
> “minimizing disease activity through flare prevention”

Source: [Barker et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39844356/)

## Related pages
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis.md)
- [Imsidolimab in Generalized pustular psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations.md)
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/executive-summary.md)
- [Imsidolimab in Generalized pustular psoriasis: Clinical evidence](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/clinical-evidence.md)
- [Imsidolimab in Generalized pustular psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economics.md)
- [Imsidolimab in Generalized pustular psoriasis: References](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/references.md)
- [Imsidolimab in Generalized pustular psoriasis: prevalence by geography](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/prevalence) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/prevalence.md)
- [Imsidolimab in Generalized pustular psoriasis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/cost-effectiveness-analyses.md)
